Dr. Jula Inrig is a Senior Medical Director and Global Therapeutic Strategy Lead in Nephrology at Quintiles. Dr. Inrig provides Quintiles clients a full range of strategic expertise from formulation of drug development plans, planning and designing trials, endpoint committees, DSMB, protocol writing, FDA/EMA meetings, global medical oversight, regulatory submissions, feasibility, due diligence, market analysis, and commercialization support.
Dr. Inrig is board certified in Nephrology and Internal Medicine and has a Masters of Health Science (MHS) in Clinical Research from Duke. She has a 10 year tenure as an academic clinical scientist with 40+ publications in peer-reviewed literature and PI and industry consultant for numerous clinical trials. She is an Adjunct Associate in Medicine at Duke University and Duke Clinical Research Institute and a member of the Inaugural Board of Directors for KHI (Kidney Health Initiative, a public-private partnership with the FDA designed to improve drug development within nephrology).
Additionally, she is an active member on the KDOQI work group for Dialysis Adequacy Guidelines, Chair on American Heart Association Kidney Council in Cardiovascular Disease and serves on the editorial board for Kidney International. Dr. Inrig has served as a Global Medical and Scientific Advisor for more than 15 Phase II-IV clinical trials within nephrology.